Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

NCT03474458 is registered in ClinicalTrials.gov with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor.

NCT NCT03474458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Phase 2/3
Overall status
Terminated
Start date
February 11, 2019
Completion date
May 30, 2022
Enrollment
19 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac al amyloidosis